Results of the Phase 1 Trial of RG7112, a Small-molecule MDM2 Antagonist in Leukemia

PURPOSE: RG7112 is a small-molecule MDM2 antagonist. MDM2 is a negative regulator of the tumor suppressor p53 and frequently overexpressed in leukemias. Thus, a Phase I study of RG7112 in patients with hematologic malignancies was conducted. EXPERIMENTAL DESIGN: Primary study objectives included det...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Andreeff, Michael, Kelly, Kevin R., Yee, Karen, Assouline, Sarit, Strair, Roger, Popplewell, Leslie, Bowen, David, Martinelli, Giovanni, Drummond, Mark W., Vyas, Paresh, Kirschbaum, Mark, Iyer, Swaminathan Padmanabhan, Ruvolo, Vivian, Nogueras González, Graciela M., Huang, Xuelin, Chen, Gong, Graves, Bradford, Blotner, Steven, Bridge, Peter, Jukofsky, Lori, Middleton, Steve, Reckner, Monica, Rueger, Ruediger, Zhi, Jianguo, Nichols, Gwen, Kojima, Kensuke
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4809642/
https://ncbi.nlm.nih.gov/pubmed/26459177
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0481
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados